Yıl: 2019 Cilt: 44 Sayı: 4 Sayfa Aralığı: 452 - 461 Metin Dili: İngilizce DOI: 10.1515/tjb-2018-0155 İndeks Tarihi: 05-06-2020

Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways

Öz:
Objective: This study aimed to investigate the renoprotec- tive effects of paricalcitol, a synhetic vitamin D analog, through its possible roles on p38 MAPK and PI3K/Akt signaling pathways to prevent oxidative stress, inflamma- tion and apoptosis during renal I/R.Materials and methods: Total 20 kidney tissues of sham (n  6), subjected to renal I/R bilaterally for 45 min ischemia followed by 24 h reperfusion (n  7) and parical- citol (0.3 g/kg, ip) pretreated Wistar albino rats (n  7) were used in this study. Interstitial inflammation and active caspase-3 expression were evaluated histologically. TNF-, IL-1, kidney injury molecule-1 (KIM-1), MDA and SOD activity in kidneys were analysed biochemically. Fur- thermore, activation of p38 MAPK, PI3K/Akt signaling pathways and NFB p65 were evaluated by western blot. Results: Paricalcitol pretreatment significantly reduced interstitial inflammation during renal I/R, which was consistent with decreased tumor TNF-, IL-1, active caspase-3 and KIM-1 expression. Paricalcitol also reduced MDA level and attenuated the reduction of SOD activity in the kidney during I/R. Moreover, paricalcitol could suppress the p38 MAPK and NFB p65, and also activate PI3K/Akt signaling pathway during renal I/R. Conclusion: All these findings indicate that paricalcitol may be an effective practical strategy to prevent renal I/R injury.
Anahtar Kelime:

Parikalsitol renal iskemi/reperfüzyon hasarını p38 MAPK aktivasyonunu inhibe ederek ve PI3K/Akt’ı aktive ederek azaltır

Öz:
Amaç: Bu çalışmanın amacı vitamin D’nin bir sentetik analoğu olan parikalsitol’ün renal iskemi/reperfüzyon (I/R) süresince oksidatif stres, inflamasyon ve apoptozise karşı renoprotektif etkisini p38 MAPK ve PI3K/Akt sinyal ileti yolakları üzerine olası rolleri ile araştırmaktır. Gereç ve yöntem: Sham (n  6) grubu, bilateral renal iskemi/reperfüzyon (I/R) (45 dak iskemi, 24 saat reperfüz- yon) (n  7) ve renal I/R’den önce parikalsitol (0.3 g/kg, i.p) (n  7) uygulanan Wistar albino sıçanlardan alınan toplam 20 böbrek dokusu kullanıldı. İnterstisyel inflamasyon ve aktif kaspaz-3 histolojik analizler ile değerlendirildi. Böbrek dokusunda TNF-, IL-1, böbrek hasar molekülü-1 (KIM-1), MDA ve SOD biyokimyasal olarak analiz edildi. p38 MAPK, PI3K/Akt sinyal yolaklarının aktivasyonu ve NFB p65 Western blot ile değerlendirildi. Bulgular: Parikalsitol, renal I/R süresince oluşan interstis- yel inflamasyonu anlamlı olarak azalttı. Bununla ilişkili olarak renal I/R süresince artan TNF-, IL-1, aktif kaspaz-3 ve KIM-1 parikalsitol ile anlamlı olarak azaldı. Parikalsitol ile aynı zamanda renal I/R süresince böbrek dokusunda artan MDA seviyesi anlamlı olarak azalırken, SOD aktivite düzeyi ise anlamlı olarak arttı. Ayrıca parikalsitolün renal I/R süresince artan p38 MAPK aktivasyonunu ve NFB p65 protein ifadesini baskılayabildiği ve PI3K/Akt sinyal ileti yolağını da aktive edebildiği saptandı. Sonuç: Tüm bu bulgular parikalsitol’ün renal I/R hasarına karşı geliştirilen stratejilerde aday olabileceğine işaret etmektedir.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
1
1
  • 1. Chatterjee PK. Novel pharmacological approaches to the treat- ment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007;376:1–43.
  • 2. Reel B, Guzeloglu M, Bagriyanik A, Atmaca S, Aykut K, Albayrak G, et al. The effects of PPAR- agonist pioglitazone on renal ischemia/reperfusion injury in rats. J Surg Res 2013;182:176–84.
  • 3. Ahmadiasl N, Banaei S, Alihemati A, Baradaran B, Azimian E. Effect of a combined treatment with erythropoietin and mela- tonin on renal ischemia reperfusion injury in male rats. Clin Exp Nephrol 2014;18:855–64.
  • 4. Son Y, Cheong YK, Kim NH, Chung HT, Kang DG, Pae HO, et al. Mitogen-activated protein kinases and reactive oxygen spe- cies: how can ROS activate MAPK pathways? J Signal Transduct 2011;2011:792639.
  • 5. Thurman JM. Triggers of inflammation after renal ischemia/rep- erfusion. Clin Immunol 2007;123:7–13.
  • 6. Luo F, Shi J, Shi Q, Xu X, Xia Y, He, X. Mitogen-activated protein kinases and hypoxic/ischemic nephropathy. Cell Physiol Bio- chem 2016;39:1051–67.
  • 7. Ye S, Zhu Y, Ming Y, She X, Liu H, Ye Q. Glycyrrhizin protects mice against renal ischemia-reperfusion injury through inhibition of apoptosis and inflammation by downregulating p38 mitogen- activated protein kinase signaling. Exp Ther Med 2014;7:1247–52.
  • 8. Cavdar Z, Ural C, Celik A, Arslan S, Terzioglu G, Ozbal S, et al. Protective effects of taurine against renal ischemia/reperfusion injury in rats by inhibition of gelatinases, MMP-2 and MMP-9, and p38 mitogen-activated protein kinase signaling. Biotech Histochem 2017;92:524–35.
  • 9. Xie L, Zheng X, Qin J, Chen Z, Jin Y, Ding W. Role of PI3-kinase/ Akt signalling pathway in renal function and cell proliferation after renal ischaemia/reperfusion injury in mice. Nephrology (Carlton) 2006;11:207–12.
  • 10. Zhang J, Zou YR, Zhong X, Deng HD, Pu L, Peng K, et al. Erythropoietin pretreatment ameliorates renal ischaemia- reperfusion injury by activating PI3K/Akt signalling. Nephrology (Carlton) 2015;20:266–72.
  • 11. Cunningham J, Zehnder D. New vitamin D analogs and changing therapeutic paradigms. Kidney Int 2011;79:702–7.
  • 12. Park JW, Bae EH, Kim IJ, Ma SK, Choi C, Lee J, et al. Paricalcitol attenuates cyclosporine-induced kidney injury in rats. Kidney Int 2010;77:1076–85.
  • 13. Park JW, Bae EH, Kim IJ, Ma SK, Choi C, Lee J, et al. Renoprotec- tive effects of paricalcitol on gentamicin-induced kidney injury in rats. Am J Physiol Renal Physiol 2010;298:F301–13.
  • 14. Bulut G, Basbugan Y, Ari E, Erten R, Bektas H, Alp HH, et al. Paricalcitol may improve oxidative DNA damage on experimental amikacin-induced nephrotoxicity model. Ren Fail 2016;38:751–8.
  • 15. Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, Valcheva P, Gracia O, Ibarz M, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropa- thy. Am J Physiol Renal Physiol 2012;302:F647–57.
  • 16. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 2008;19:1741–52.
  • 17. Azak A, Huddam B, Haberal N, Kocak G, Ortabozkoyun L, Şenes M, et al. Effect of novel vitamin D receptor activator paricalcitol on renal ischaemia/reperfusion injury in rats. Ann R Coll Surg Engl 2013;95:489–94.
  • 18. Hwang HS, Yang KJ, Park KC, Choi HS, Kim SH, Hong SY, et al. Pretreatment with paricalcitol attenuates inflammation in ischemia-reperfusion injury via the up-regulation of cyclooxy- genase-2 and prostaglandin E2. Nephrol Dial Transplant 2013;28:1156–66.
  • 19. Lee JW, Kim SC, Ko YS, Lee HY, Cho E, Kim MG, et al. Renoprotective effect of paricalcitol via a modulation of the TLR4-NF-B pathway in ischemia/reperfusion-induced acute kidney injury. Biochem Biophys Res Commun 2014;444: 121–7.
  • 20. Hong YA, Yang KJ, Jung SY, Park KC, Choi H, Oh JM, et al. Pari- calcitol pretreatment attenuates renal ischemia-reperfusion injury via prostaglandin E2 Receptor EP4 Pathway. Oxid Med Cell Longev 2017;2017:5031926.
  • 21. Ersan S, Celik A, Tanrisev M, Kose I, Cavdar Z, Unlu M, et al. Pretreatment with paricalcitol attenuates level and expression of matrix metalloproteinases in a rat model of renal ischemia- reperfusion injury. Clin Nephrol 2017;88:231–8.
  • 22. Yasuda H, Yuen PS, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 2006;69:1535–42.
  • 23. Lykkesfeldt J. Determination of malondialdehyde as dithio- barbituric acid adduct in biological samples by HPLC with fluorescence detection: comparison with ultraviolet-visible spectrophotometry. Clin Chem 2001;47:1725–7.
  • 24. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101–08.
  • 25. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680–5.
  • 26. Wiechelman KJ, Braun RD, Fitzpatrick JD. Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 1988;175:231–7.
  • 27. Dennis JM, Witting PK. Protective role for antioxidants in acute kidney disease. Nutrients 2017;9. pii: E718. DOI: 10.3390/nu9070718.
  • 28. Chung S, Kim S, Kim M, Koh ES, Shin SJ, Park CW, et al. Treat- ment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. PLoS One 2017;28;12:e0181757.
  • 29. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001;59:415–24.
  • 30. Yang B, Jain S, Ashra SY, Furness PN, Nicholson ML. Apoptosis and caspase-3 in long-term renal ischemia/reperfusion injury in rats and divergent effects of immunosuppressants. Transplanta- tion 2006;81:1442–50.
  • 31. Wang YP, Li G, Ma LL, Zheng Y, Zhang SD, Zhang HX, et al. Pene- hyclidine hydrochloride ameliorates renal ischemia-reperfusion injury in rats. J Surg Res 2014;186:390–7.
  • 32. Suh SH, Lee KE, Park JW, Kim IJ, Kim O, Kim CS, et al. Antiapoptotic effect of paricalcitol in gentamicin-induced kidney injury. Korean J Physiol Pharmacol 2013;17:435–40.
  • 33. Yang L, Brooks CR, Xiao S, Sabbisetti V, Yeung MY, Hsiao LL, et al. KIM-1-mediated phagocytosis reduces acute injury to the kidney. J Clin Invest 2015;125:1620–36.
  • 34. Xie H, Li J, Gao H, Wang J, Li C, Xu Y, et al. Total flavone of Desmo- dium styracifolium relieved apoptosis and autophagy of COM- induced HK-2 cells by regulating KIM-1 via p38/MAPK pathway. Mol Cell Biochem 2018;442:169–75.
  • 35. de Souza AJ, Oak JS, Jordanhazy R, DeKruyff RH, Fruman DA, Kane LP. T cell Ig and mucin domain-1-mediated T cell activa- tion requires recruitment and activation of phosphoinositide 3-kinase. J Immunol 2008;180:6518–26.
APA Cavdar Z, ural c, Koçak A, arslan s, ERSAN S, Özbal S, TATLI M, DUBOVA A, ÇAVDAR C (2019). Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways. , 452 - 461. 10.1515/tjb-2018-0155
Chicago Cavdar Zahide,ural cemre,Koçak Ayşe,arslan sevki,ERSAN Sibel,Özbal Seda,TATLI Merve,DUBOVA Aslı,ÇAVDAR Caner Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways. (2019): 452 - 461. 10.1515/tjb-2018-0155
MLA Cavdar Zahide,ural cemre,Koçak Ayşe,arslan sevki,ERSAN Sibel,Özbal Seda,TATLI Merve,DUBOVA Aslı,ÇAVDAR Caner Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways. , 2019, ss.452 - 461. 10.1515/tjb-2018-0155
AMA Cavdar Z,ural c,Koçak A,arslan s,ERSAN S,Özbal S,TATLI M,DUBOVA A,ÇAVDAR C Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways. . 2019; 452 - 461. 10.1515/tjb-2018-0155
Vancouver Cavdar Z,ural c,Koçak A,arslan s,ERSAN S,Özbal S,TATLI M,DUBOVA A,ÇAVDAR C Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways. . 2019; 452 - 461. 10.1515/tjb-2018-0155
IEEE Cavdar Z,ural c,Koçak A,arslan s,ERSAN S,Özbal S,TATLI M,DUBOVA A,ÇAVDAR C "Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways." , ss.452 - 461, 2019. 10.1515/tjb-2018-0155
ISNAD Cavdar, Zahide vd. "Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways". (2019), 452-461. https://doi.org/10.1515/tjb-2018-0155
APA Cavdar Z, ural c, Koçak A, arslan s, ERSAN S, Özbal S, TATLI M, DUBOVA A, ÇAVDAR C (2019). Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways. Türk Biyokimya Dergisi, 44(4), 452 - 461. 10.1515/tjb-2018-0155
Chicago Cavdar Zahide,ural cemre,Koçak Ayşe,arslan sevki,ERSAN Sibel,Özbal Seda,TATLI Merve,DUBOVA Aslı,ÇAVDAR Caner Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways. Türk Biyokimya Dergisi 44, no.4 (2019): 452 - 461. 10.1515/tjb-2018-0155
MLA Cavdar Zahide,ural cemre,Koçak Ayşe,arslan sevki,ERSAN Sibel,Özbal Seda,TATLI Merve,DUBOVA Aslı,ÇAVDAR Caner Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways. Türk Biyokimya Dergisi, vol.44, no.4, 2019, ss.452 - 461. 10.1515/tjb-2018-0155
AMA Cavdar Z,ural c,Koçak A,arslan s,ERSAN S,Özbal S,TATLI M,DUBOVA A,ÇAVDAR C Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways. Türk Biyokimya Dergisi. 2019; 44(4): 452 - 461. 10.1515/tjb-2018-0155
Vancouver Cavdar Z,ural c,Koçak A,arslan s,ERSAN S,Özbal S,TATLI M,DUBOVA A,ÇAVDAR C Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways. Türk Biyokimya Dergisi. 2019; 44(4): 452 - 461. 10.1515/tjb-2018-0155
IEEE Cavdar Z,ural c,Koçak A,arslan s,ERSAN S,Özbal S,TATLI M,DUBOVA A,ÇAVDAR C "Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways." Türk Biyokimya Dergisi, 44, ss.452 - 461, 2019. 10.1515/tjb-2018-0155
ISNAD Cavdar, Zahide vd. "Paricalcitol pretreatment attenuates renal ischemia/reperfusion injury by inhibiting p38 MAPK and activating PI3K/Akt signaling pathways". Türk Biyokimya Dergisi 44/4 (2019), 452-461. https://doi.org/10.1515/tjb-2018-0155